Efficacy of Kangliuwan for Recurrent Grade IV Glioma

NCT ID: NCT03949192

Last Updated: 2020-05-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-28

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Prospective Exploratory Clinical Study to explore the efficacy of Hospital Traditional Chinese Medicine Preparation Kangliuwan for Recurrent Grade IV Glioma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioma of Brain Recurrence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The patient signed "informed consent" voluntarily;
2. The age of patient is between 18 and 80 years;
3. KPS score ≥40 ; The patient has normal liver and kidney function Normal heart function Better follow-up and compliance;

Exclusion Criteria

1. The patient did not sign "informed consent" or signed unvoluntarily.
2. Non-glioma patients
3. Active infection
4. Human immunodeficiency virus (HIV) positive
5. Hepatitis C or hepatitis B infective
6. Pregnancy or breast-feeding women
7. Patients did not agree to use effective contraception during treatment and the following 3 months.
8. Patients also participated in other clinical studies.
9. The subjects researchers believe are not suitable for participation or completion of the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xuanwu Hospital, Beijing

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Qingtang Lin

assistant director physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Qingtang Lin, M.D., Ph.D.

Role: STUDY_CHAIR

Xuanwu Hospital, Beijing

Xiaolan Lin, M.D.

Role: PRINCIPAL_INVESTIGATOR

Xuanwu Hospital, Beijing

Ling Chen, M.D.

Role: PRINCIPAL_INVESTIGATOR

The General Hospital of People's Liberation Army (301 hospital)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Xuanwu Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Qingtang Lin, MD. Ph.D

Role: CONTACT

8610-83198362

Ge Sun, B.A.

Role: CONTACT

8610-83198362

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ge Sun, B.A.

Role: primary

8610-83168899

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LYS [2019] 027

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

68Ga-P16-093 PET/CT Imaging in Glioma Patients
NCT05569434 UNKNOWN PHASE1/PHASE2